227 related articles for article (PubMed ID: 33567773)
21. Mechanism of the enhanced intrinsic activity of single-chain urokinase-type plasminogen activator during ongoing fibrinolysis.
Fleury V; Lijnen HR; Anglés-Cano E
J Biol Chem; 1993 Sep; 268(25):18554-9. PubMed ID: 8103046
[TBL] [Abstract][Full Text] [Related]
22. Dysfibrinogenemia (fibrinogen Dusard) associated with impaired fibrin-enhanced plasminogen activation.
Lijnen HR; Soria J; Soria C; Collen D; Caen JP
Thromb Haemost; 1984 Feb; 51(1):108-9. PubMed ID: 6539000
[TBL] [Abstract][Full Text] [Related]
23. Histidine-rich glycoprotein and alpha 2-plasmin inhibitor in inhibition of plasminogen binding to fibrin.
Ichinose A; Mimuro J; Koide T; Aoki N
Thromb Res; 1984 Feb; 33(4):401-7. PubMed ID: 6710439
[TBL] [Abstract][Full Text] [Related]
24. What drives "fibrinolysis"?
Medcalf RL
Hamostaseologie; 2015; 35(4):303-10. PubMed ID: 25564072
[TBL] [Abstract][Full Text] [Related]
25. Bivalency of plasminogen monoclonal antibodies is required for plasminogen bridging to fibrin and enhanced plasmin formation.
Dominguez M; Montes R; Páramo JA; Anglés-Cano E
Biochim Biophys Acta; 2002 Jul; 1598(1-2):165-76. PubMed ID: 12147357
[TBL] [Abstract][Full Text] [Related]
26. Fibrinolysis-resistant carbonylated fibrin detected in thrombi attached to the vascular wall of abdominal aortic aneurysms.
Suzuki Y; Tanaka H; Horinouchi T; Sano H; Honkura N; Unno N; Miwa S; Urano T
Sci Rep; 2020 Nov; 10(1):20728. PubMed ID: 33244022
[TBL] [Abstract][Full Text] [Related]
27. The fibrogenic actions of the coagulant and plasminogen activation systems in pulmonary fibrosis.
Schuliga M; Grainge C; Westall G; Knight D
Int J Biochem Cell Biol; 2018 Apr; 97():108-117. PubMed ID: 29474926
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of fibrinolysis by lipoprotein(a).
Anglés-Cano E; de la Peña Díaz A; Loyau S
Ann N Y Acad Sci; 2001; 936():261-75. PubMed ID: 11460483
[TBL] [Abstract][Full Text] [Related]
29. Fibrinolysis as a Target to Enhance Fracture Healing.
O'Keefe RJ
N Engl J Med; 2015 Oct; 373(18):1776-8. PubMed ID: 26510027
[No Abstract] [Full Text] [Related]
30. Plasminogen receptors and their role in the pathogenesis of inflammatory, autoimmune and malignant disease.
Godier A; Hunt BJ
J Thromb Haemost; 2013 Jan; 11(1):26-34. PubMed ID: 23140188
[TBL] [Abstract][Full Text] [Related]
31. Interactions of plasminogen with polymerizing fibrin and its derivatives, monitored with a photoaffinity cross-linker and electron microscopy.
Weisel JW; Nagaswami C; Korsholm B; Petersen LC; Suenson E
J Mol Biol; 1994 Jan; 235(3):1117-35. PubMed ID: 8289311
[TBL] [Abstract][Full Text] [Related]
32. Interactions between staphylokinase, plasmin(ogen), and fibrin. Staphylokinase discriminates between free plasminogen and plasminogen bound to partially degraded fibrin.
Sakharov DV; Lijnen HR; Rijken DC
J Biol Chem; 1996 Nov; 271(44):27912-8. PubMed ID: 8910391
[TBL] [Abstract][Full Text] [Related]
33. Defective thrombolysis due to collagen incorporation in fibrin clots.
Mirshahi M; Soria J; Lu H; Soria C; Samama M; Caen JP
Thromb Res Suppl; 1988; 8():73-80. PubMed ID: 3144770
[TBL] [Abstract][Full Text] [Related]
34. A review of the basic mechanisms of fibrinogen to fibrin conversion and of fibrinolysis: intravascular coagulation versus primary fibrinolysis.
Colick JA; Fisher LM
Va Med Mon (1918); 1970 May; 97(5):310-4 passimass. PubMed ID: 4276992
[No Abstract] [Full Text] [Related]
35. A precise and rapid microtitre plate clot lysis assay: methodology, kinetic modeling and measurement of catalytic constants for plasminogen activation during fibrinolysis.
Jones AJ; Meunier AM
Thromb Haemost; 1990 Nov; 64(3):455-63. PubMed ID: 2128976
[TBL] [Abstract][Full Text] [Related]
36. Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.
Wu JH; Diamond SL
J Clin Invest; 1995 Jun; 95(6):2483-90. PubMed ID: 7769094
[TBL] [Abstract][Full Text] [Related]
37. Stimulation of tPA-dependent provisional extracellular fibrin matrix degradation by human recombinant soluble melanotransferrin.
Bertrand Y; Demeule M; Rivard GE; Béliveau R
Biochim Biophys Acta; 2006 Oct; 1763(10):1024-30. PubMed ID: 16979249
[TBL] [Abstract][Full Text] [Related]
38. [PC-12 cells hydrolyze the fibrin clot by producing both plasminogen and its tissue activator].
Petrova IuI; Savchuk OM; Kalashnyk OM; Platonova TM; Skok MV; Cederholm-Williams S
Ukr Biokhim Zh (1999); 2004; 76(2):64-8. PubMed ID: 15915713
[TBL] [Abstract][Full Text] [Related]
39. Importance of the interaction between plasminogen and fibrin for plasminogen activation by tissue-type plasminogen activator.
Dunn FW; Deguchi K; Soria J; Soria C; Lijnen HR; Tobelem G; Caen J
Thromb Res; 1984 Nov; 36(4):345-51. PubMed ID: 6543039
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms of physiological fibrinolysis.
Lijnen HR; Collen D
Baillieres Clin Haematol; 1995 Jun; 8(2):277-90. PubMed ID: 7549063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
